Tag: ALTUVIIIO
Sanofi: ALTUVIIIO approved by the US FDA, a positive impact on IFRS 2022 net income
By Claude Leguilloux Published on 02/24/2023 at 6:25 p.m. Photo credit © Sanofi (Boursier.com) — Sanofi announces…
ALTUVIIIO™ approved by the US FDA: this positive event triggers an impairment reversal, which has a positive impact on the IFRS 2022 net income; no change in net income from operations (non-IFRS) – 02/24/2023 at 17:16
US FDA Approves ALTUIIIO TM once a week, a new class of factor VIII for the treatment of hemophilia A that confers significant protection against bleeding. This positive event triggers…